Direct Sales vs. Channel Partners in Healthcare IT: The Real Decision Criteria | NPLUS Global

Most vendors treat this as a binary, values-laden choice — "we build direct relationships" versus "we scale through partners" — when it's actually a segmentation problem with a compliance layer bolted on. The right answer usually isn't one or the other; it's knowing which accounts, products, and deal types belong in which motion. Here's what actually determines the split, based on how healthcare IT go-to-market decisions tend to play out in practice.

1. Start with who's actually buying, not your org chart. A CIO evaluating infrastructure, a CMIO evaluating clinical workflow tools, and a department director buying a point solution for radiology are three different buyers with three different tolerance levels for talking to a reseller instead of the vendor. If your product touches clinical workflow or requires physician buy-in, direct engagement tends to build trust faster than a partner rep who can't speak credibly to clinical nuance — that credibility gap is real and it shows up in stalled deals.
2. Integration depth should drive the channel decision more than deal size does. A product that requires real HL7/FHIR interface work, Epic Bridges or Oracle Health interface builds, or deep EHR configuration is functionally an implementation project disguised as a sale — and implementation partners who don't own that complexity will underscope it, creating a support and credibility problem for you six months post-close. Lighter-touch, more standardized products (imaging viewers, secure messaging add-ons, certain RCM point tools) integrate more predictably and travel through channel partners without the same risk.
3. The long tail is where channel economics actually make sense. Large IDNs and academic medical centers can justify a dedicated direct rep because the deal size and expansion potential support the cost of coverage; the thousands of critical access hospitals, rural health clinics, and small multi-specialty groups cannot. This is the honest argument for distributors, VARs, and regional resellers — not "scale," but the math of covering accounts too small individually to justify a quota-carrying rep, but collectively too large to ignore.
4. GPO and IDN contracts are a channel in disguise, and they change the sales motion entirely. Once a product sits on a group purchasing organization contract or an IDN's approved vendor list, the sales job shifts from negotiating price to driving activation inside member facilities — a fundamentally different skill set than closing net-new logos. Vendors who treat GPO placement as the finish line rather than the starting line consistently underperform their contract's theoretical reach, because nobody is doing the unglamorous work of getting individual facility administrators to actually adopt.
5. EHR marketplaces are a newer, stranger hybrid worth treating separately. Listings on Epic's Showroom, Oracle Health's marketplace, or athenahealth's ecosystem give you discoverability and a technical certification stamp, but they rarely close deals on their own — buyers still expect a human sales process, they just start it with more pre-qualified trust in your interoperability claims. Treat marketplace presence as a credibility asset that supports direct or channel selling, not as a self-service acquisition channel, because in healthcare IT almost nothing actually is.
6. Compliance and security review ownership is the point most vendors underprice in channel deals. When a partner is selling on your behalf, the BAA negotiation, the security questionnaire, the SOC 2 documentation request, and the legal back-and-forth over data handling still ultimately land on you — but you often don't find out a review is stalled until the partner has already lost momentum with the buyer. Direct sales teams internalize this friction as part of the job; channel partners frequently see it as your problem to solve on their timeline, which creates deals that die quietly in legal review with no one advocating to push them through.
7. You lose account-level data visibility the moment a partner owns the relationship, and that costs you at renewal. Once a reseller or VAR closes and implements a deal, you often lose direct insight into usage patterns, champion turnover, or expansion signals inside that account — the exact intent and engagement data that predicts churn or upsell opportunity. This is a real operational cost that rarely gets modeled into channel margin decisions; some vendors address it by layering in third-party account intelligence (firms like NPLUS Global exist partly because of this gap) so they retain visibility into partner-managed accounts even without a direct relationship.
8. Margin math and channel conflict will surface eventually — plan for it before it happens. Healthcare IT partners typically expect meaningful margin for taking on implementation and support risk, and if your direct sales team is quietly working the same accounts at list price, you'll create deal registration disputes and partner resentment that surface at the worst possible time — usually mid-negotiation on your largest deal of the quarter. Formal deal registration and account mapping aren't bureaucratic overhead; they're the only thing preventing your own team from being the reason a partner stops selling your product.
9. The realistic answer is a segmented hybrid, not a company-wide policy. Strategic accounts — large IDNs, health systems with complex integration needs, anything requiring clinical credibility to close — belong with a direct or high-touch overlay motion. Community hospitals, ambulatory groups, and standardized point solutions belong with partners who already have the regional relationships and support infrastructure to serve them profitably. Vendors that pick one motion for the entire market either overspend covering accounts that don't justify it or underserve the complex deals that actually need a human who understands both the product and the clinical workflow it's touching.

The vendors that get this right revisit the split at least annually, because a product's channel fit shifts as it matures — what required white-glove direct selling at launch often becomes channel-appropriate once implementation is standardized and the sales story is repeatable. Treating the direct-versus-channel decision as permanent, rather than a function of product maturity and account segment, is usually the actual mistake — not picking the wrong motion in the first place.